On Tuesday,Shares of Southwest Airlines Co (NYSE:LUV), SUBTRACT -1.46% and closed at $39.16 in the last trading session. The last trading range of the stock ranges between $39.09 and $40.49. Southwest Airlines Co. (LUV) is launching a three-day sale offering extra low fares for winter travel, so book your next trip now! Customers may take advantage of low domestic fares starting at $49, $79, $99, and $129 one-way to select destinations recently through Thursday, Oct. 6, 2016, 11:59 p.m. in the respective time zone of the originating city. Seats and days are limited.
Customers may also book flights to international destinations with some of Southwest’s low international fares starting at $99 one-way to select destinations recently through Thursday, Oct. 6, 2016, 11:59 p.m. in the respective time zone of the originating city. Seats and days are limited.
Depomed Inc (NASDAQ:DEPO), DROPPED -0.86% and closed at $25.36 in the last trading session. The last trading range of the stock ranges between $25.00 and $25.75. The company’s Market capitalization is $1.59 Billion with the total Outstanding Shares of 61.37 million. Depomed, Inc. (DEPO) recently declared that Judge Claire C. Cecchi of the United States District Court for the District of New Jersey has ruled in favor of Depomed in the company’s patent litigation against all three filers of Abbreviated New Drug Applications (ANDAs) for Depomed’s NUCYNTA franchise. With the court’s ruling, Depomed anticipates market exclusivity until December 2025 for NUCYNTA® ER, NUCYNTA® and NUCYNTA® oral solution (an unmarketed form of NUCYNTA). 1
“We are happy with the Court’s decision as it confirms the validity and strength of the NUCYNTA patents,” said Jim Schoeneck, President and CEO of Depomed. “We look forward to growing the NUCYNTA franchise, comprised of two important and highly-differentiated medicines, for at least the next 9 years.”
The court found U.S. patent Nos. 7,994,364 and RE39,593 to be valid and infringed by the defendants. The patents cover the entire NUCYNTA franchise and will expire on December 27, 2025 and February 5, 2023, respectively.1 Judge Cecchi upheld the validity of U.S. Patent No. 8,536,130 (the “130 Patent”), but found that two of the three filers do not infringe the patent. The ‘130 Patent covers NUCYNTA ER until March 2029. 1 The company intends to appeal the court’s finding as it relates to infringement of the ‘130 Patent.
News Corp (NASDAQ:NWSA), LOST -1.04% and closed at $14.28 in the last trading session. The last trading range of the stock ranges between $14.19 and $14.51. During the 52-week trading session the minimum price at which share price traded, registered at $10.21 and reached to max level of $15.68. For board members and shareholders alike, revenue growth is one of the easiest ways to evaluate the long-term health of large publicly traded companies.
That growth can be very difficult to predict. Companies can attempt to ensure growth through diversification and risk administration. There are many forces entirely outside of the control of corporate governance, however, such as changing commodity prices or an unanticipated shift in a market.
24/7 Wall St. reviewed the most recent three-year annual revenue changes of S&P 500 companies. Based on its 252.3% revenue growth in the last three years, Facebook is America’s fastest growing company. Netflix rounds out the list with a three-year revenue growth of 87.8%.